NERx Biosciences is focused on the discovery and development of targeted therapeutics for cancer, emphasizing innovative approaches to combat the disease. Established in 2009, the company specializes in creating novel biopharmaceutical compounds, particularly small molecule inhibitors that target specific cellular processes that are not currently utilized in cancer therapies. Their research is primarily conducted in-house, supplemented by collaborations and the acquisition of orphan intellectual property. A significant aspect of their work involves targeting the DNA damage response, which is crucial in the context of cancer treatment, as many effective chemotherapeutics, such as cisplatin, operate by damaging DNA.

The company is also engaged in preclinical studies to evaluate the efficacy and safety of their compounds, such as the NERx-80 class of compounds that target the XPA protein involved in DNA repair. Preliminary in-vivo studies have shown limited toxicity in animal models, indicating a promising safety profile for these compounds. NERx Biosciences aims to advance its pipeline through rigorous research and development, with a commitment to innovation in cancer therapeutics, as highlighted by their ongoing publications and collaborations with academic institutions like Indiana University School of Medicine.

United States

NĒRx BioSciences Inc is a company dedicated to the discovery and development of targeted therapeutics for cancer. Formed in 2009, we specialize in the discovery and development of targeted therapeutics for cancer.

NERx Biosciences

Company Details